Effect of Candesartan and Ramipril on Liver Fibrosis in Patients with Chronic Hepatitis C Viral Infection: A Randomized Controlled Prospective Study

Mostafa, Tarek; El-Azab, Gamal A.; Badra, Gamal; Abdelwahed, Alyaa S.; Elsayed, Abeer A.

doi:10.1016/j.curtheres.2021.100654

Cited by 3 publications

(1 citation statement)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DHEA significantly increased AR levels in the epidermis. A significant increase in the expression of types 1 and 3 procollagens, as well as HSP47, a procollagen chaperone protein, was observed in the dermis [ 110 ]. The potent stimulatory effect of topical DHEA on the number and size of dermal fibroblasts as well as the expression of procollagen types 1 and 3 suggests that topical DHEA may be a useful anti-aging agent in the skin [ 111 ].…”

Section: Introductionmentioning

confidence: 99%

Targeting HSP47 and HSP70: promising therapeutic approaches in liver fibrosis management

El-Fattah

Zakaria

2022

J Transl Med

View full text Add to dashboard Cite

Liver fibrosis is a liver disease in which there is an excessive buildup of extracellular matrix proteins, including collagen. By regulating cytokine production and the inflammatory response, heat shock proteins (HSPs) contribute significantly to a wider spectrum of fibrotic illnesses, such as lung, liver, and idiopathic pulmonary fibrosis by aiding in the folding and assembly of freshly synthesized proteins, HSPs serve as chaperones. HSP70 is one of the key HSPs in avoiding protein aggregation which induces its action by sending unfolded and/or misfolded proteins to the ubiquitin–proteasome degradation pathway and antagonizing influence on epithelial-mesenchymal transition. HSP47, on the other hand, is crucial for boosting collagen synthesis, and deposition, and fostering the emergence of fibrotic disorders. The current review aims to provide light on how HSP70 and HSP47 affect hepatic fibrogenesis. Additionally, our review looks into new therapeutic approaches that target HSP70 and HSP47 and could potentially be used as drug candidates to treat liver fibrosis, especially in cases of comorbidities.

show abstract

Section: Introductionmentioning

confidence: 99%

Targeting HSP47 and HSP70: promising therapeutic approaches in liver fibrosis management

El-Fattah

Zakaria

2022

J Transl Med

View full text Add to dashboard Cite

show abstract

Repurposing of drug molecules from FDA database against Hepatitis C virus E2 protein using ensemble docking approach

et al. 2023

View full text Add to dashboard Cite

The role of ACE inhibitors and ARBs in preserving cognitive function via hypertension Management: A critical Update

Yasmin,

Ashique,

Taj

et al. 2025

Brain Research

View full text Add to dashboard Cite

Effect of Candesartan and Ramipril on Liver Fibrosis in Patients with Chronic Hepatitis C Viral Infection: A Randomized Controlled Prospective Study

Abstract: Highlights Ramipril and Candesartan seem safe and effective in improving liver stiffness Candesartan maintained anti-fibrotic more effectively than Ramipril Candesartan may represent a safe and effective therapeutic strategy for liver fibrosis in patients with chronic liver diseases.

Cited by 3 publications

References 48 publications

Targeting HSP47 and HSP70: promising therapeutic approaches in liver fibrosis management

Targeting HSP47 and HSP70: promising therapeutic approaches in liver fibrosis management

Repurposing of drug molecules from FDA database against Hepatitis C virus E2 protein using ensemble docking approach

The role of ACE inhibitors and ARBs in preserving cognitive function via hypertension Management: A critical Update

Contact Info

Product

Resources

About